Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptor...

Full description

Saved in:
Bibliographic Details
Main Authors: Albayrak, Yakup, Hashimoto, Kenji
Format: Artigo
Language:Inglês
Published: Korean Neuropsychiatric Association 2013
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3902161/
https://ncbi.nlm.nih.gov/pubmed/24474992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4306/pi.2013.10.4.417
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items